Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Epidemiology, pathogenesis, and clinical manifestations of lymphatic filariasis

Amy D Klion, MD
Section Editor
Peter F Weller, MD, FACP
Deputy Editor
Elinor L Baron, MD, DTMH


Filariasis is caused by nematodes (roundworms) that inhabit the lymphatics and subcutaneous tissues. Three filarial species cause lymphatic filariasis: Wuchereria bancrofti, Brugia malayi, and Brugia timori. Infections are transmitted by mosquito vectors; humans are definitive hosts. Lymphatic filariasis is a major cause of disfigurement and disability in endemic areas, leading to significant economic and psychosocial impact.

The epidemiology, pathogenesis, and clinical features of lymphatic filariasis will be reviewed here. The diagnosis, treatment, and prevention of lymphatic filariasis and other filarial infections, including onchocerciasis, loiasis, and mansonellosis, are discussed separately. (See "Diagnosis, treatment, and prevention of lymphatic filariasis" and "Onchocerciasis" and "Loiasis (Loa loa infection)".)


W. bancrofti occurs in sub-Saharan Africa, Southeast Asia, the Indian subcontinent, many of the Pacific islands, and focal areas of Latin America and the Caribbean (including Haiti). B. malayi occurs mainly in China, India, Malaysia, the Philippines, Indonesia, and various Pacific islands. B. timori occurs on the Timor Island of Indonesia (figure 1). Overall, approximately two-thirds of individuals infected with lymphatic filariasis are in Asia. The epidemiology of lymphatic filariasis is changing due to implementation of a global program of mass drug administration (MDA) to eliminate transmission. Not only has mapping of disease prevalence prior to MDA led to reclassification of some countries (Costa Rica, Suriname, Trinidad and Tobago) as nonendemic, but some countries, including Togo, Vietnam, Cambodia, American Samoa, the Cook Islands, the Marshall Islands, Tonga, and Vanuatu, appear to have eliminated transmission entirely [1].

It is estimated that more than 120 million people worldwide are infected. More than 90 percent of these infections are due to W. bancrofti, while the remainder is due largely to B. malayi. Estimates suggest that more than 40 million infected individuals are seriously incapacitated and disfigured by lymphatic filariasis [2]. One study in India noted that patients with chronic filariasis lose around 29 days of work per year due to complications of infection, highlighting the considerable burden the disease places on individuals and on the community [3]. Another study reported an estimated productivity loss due to lymphatic filariasis of 77 to 100 percent during attacks of acute dermatolymphangioadenitis, 10 to 26 percent for lymphedema, and 15 to 19 percent for hydrocele [4]. In addition, data suggest that the prevalence of depressive illness is high, accounting for an estimated 5.09 million disability-adjusted life years (DALYs) [5].

Lymphatic filariasis is likely first acquired in childhood; it has been suggested that as many as one-third of children are asymptomatically infected before age five [6]. The risk of infection in childhood may be related to the maternal immune response during pregnancy. In one study of 159 Kenyan pregnant women with active Wuchereria infection, neonates lacking filarial-specific T cell responses in cord blood at birth had a 13-fold increased risk of developing childhood infection (compared with uninfected controls) [7].


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Oct 4, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Global programme to eliminate lymphatic filariasis: progress report, 2013. Wkly Epidemiol Rec 2014; 89:409.
  2. Global Programme to eliminate lymphatic filariasis: progress report on mass drug administration, 2010. Wkly Epidemiol Rec 2011; 86:377.
  3. Babu BV, Swain BK, Rath K. Impact of chronic lymphatic filariasis on quantity and quality of productive work among weavers in an endemic village from India. Trop Med Int Health 2006; 11:712.
  4. Lenk EJ, Redekop WK, Luyendijk M, et al. Productivity Loss Related to Neglected Tropical Diseases Eligible for Preventive Chemotherapy: A Systematic Literature Review. PLoS Negl Trop Dis 2016; 10:e0004397.
  5. Ton TG, Mackenzie C, Molyneux DH. The burden of mental health in lymphatic filariasis. Infect Dis Poverty 2015; 4:34.
  6. Witt C, Ottesen EA. Lymphatic filariasis: an infection of childhood. Trop Med Int Health 2001; 6:582.
  7. Malhotra I, Mungai PL, Wamachi AN, et al. Prenatal T cell immunity to Wuchereria bancrofti and its effect on filarial immunity and infection susceptibility during childhood. J Infect Dis 2006; 193:1005.
  8. Baird JB, Charles JL, Streit TG, et al. Reactivity to bacterial, fungal, and parasite antigens in patients with lymphedema and elephantiasis. Am J Trop Med Hyg 2002; 66:163.
  9. King CL. Transmission intensity and human immune responses to lymphatic filariasis. Parasite Immunol 2001; 23:363.
  10. Lamb TJ, Le Goff L, Kurniawan A, et al. Most of the response elicited against Wolbachia surface protein in filarial nematode infection is due to the infective larval stage. J Infect Dis 2004; 189:120.
  11. Malhotra I, Ouma JH, Wamachi A, et al. Influence of maternal filariasis on childhood infection and immunity to Wuchereria bancrofti in Kenya. Infect Immun 2003; 71:5231.
  12. Lymphatic filariasis: diagnosis and pathogenesis. WHO expert committee on filariasis. Bull World Health Organ 1993; 71:135.
  13. Lammie PJ, Cuenco KT, Punkosdy GA. The pathogenesis of filarial lymphedema: is it the worm or is it the host? Ann N Y Acad Sci 2002; 979:131.
  14. Choi EH, Nutman TB, Chanock SJ. Genetic variation in immune function and susceptibility to human filariasis. Expert Rev Mol Diagn 2003; 3:367.
  15. Chesnais CB, Sabbagh A, Pion SD, et al. Familial Aggregation and Heritability of Wuchereria bancrofti Infection. J Infect Dis 2016; 214:587.
  16. Nutman TB, Kazura J. Lymphatic Filariasis. In: Tropical Infectious Diseases: Principles, Pathogens and Practice, 3rd ed, Guerrant R, Walker DH, Weller PF (Eds), Saunders Elsevier, Philadelphia 2011. p.729.
  17. Dissanayake S. In Wuchereria bancrofti filariasis, asymptomatic microfilaraemia does not progress to amicrofilaraemic lymphatic disease. Int J Epidemiol 2001; 30:394.
  18. Arndts K, Deininger S, Specht S, et al. Elevated adaptive immune responses are associated with latent infections of Wuchereria bancrofti. PLoS Negl Trop Dis 2012; 6:e1611.
  19. Ottesen EA. The Wellcome Trust Lecture. Infection and disease in lymphatic filariasis: an immunological perspective. Parasitology 1992; 104 Suppl:S71.
  20. Bennuru S, Nutman TB. Lymphatics in human lymphatic filariasis: in vitro models of parasite-induced lymphatic remodeling. Lymphat Res Biol 2009; 7:215.
  21. Grobusch MP, Kombila M, Autenrieth I, et al. No evidence of Wolbachia endosymbiosis with Loa loa and Mansonella perstans. Parasitol Res 2003; 90:405.
  22. Taylor MJ, Hoerauf A. Wolbachia bacteria of filarial nematodes. Parasitol Today 1999; 15:437.
  23. Punkosdy GA, Addiss DG, Lammie PJ. Characterization of antibody responses to Wolbachia surface protein in humans with lymphatic filariasis. Infect Immun 2003; 71:5104.
  24. Taylor MJ. Wolbachia in the inflammatory pathogenesis of human filariasis. Ann N Y Acad Sci 2003; 990:444.
  25. Taylor MJ, Cross HF, Ford L, et al. Wolbachia bacteria in filarial immunity and disease. Parasite Immunol 2001; 23:401.
  26. Taylor MJ. A new insight into the pathogenesis of filarial disease. Curr Mol Med 2002; 2:299.
  27. Freedman DO, de Almeida Filho PJ, Besh S, et al. Lymphoscintigraphic analysis of lymphatic abnormalities in symptomatic and asymptomatic human filariasis. J Infect Dis 1994; 170:927.
  28. Ottesen EA, Weller PF. Eosinophilia following treatment of patients with schistosomiasis mansoni and Bancroft's filariasis. J Infect Dis 1979; 139:343.
  29. Kroidl I, Saathoff E, Maganga L, et al. Effect of Wuchereria bancrofti infection on HIV incidence in southwest Tanzania: a prospective cohort study. Lancet 2016.
  30. Pani SP, Srividya A. Clinical manifestations of bancroftian filariasis with special reference to lymphoedema grading. Indian J Med Res 1995; 102:114.
  31. Pani SP, Yuvaraj J, Vanamail P, et al. Episodic adenolymphangitis and lymphoedema in patients with bancroftian filariasis. Trans R Soc Trop Med Hyg 1995; 89:72.
  32. Dreyer G, Medeiros Z, Netto MJ, et al. Acute attacks in the extremities of persons living in an area endemic for bancroftian filariasis: differentiation of two syndromes. Trans R Soc Trop Med Hyg 1999; 93:413.
  33. McPherson T, Persaud S, Singh S, et al. Interdigital lesions and frequency of acute dermatolymphangioadenitis in lymphoedema in a filariasis-endemic area. Br J Dermatol 2006; 154:933.
  34. Supali T, Wibowo H, Rückert P, et al. High prevalence of Brugia timori infection in the highland of Alor Island, Indonesia. Am J Trop Med Hyg 2002; 66:560.
  35. Sethi S, Misra K, Singh UR, Kumar D. Lymphatic filariasis of the ovary and mesosalpinx. J Obstet Gynaecol Res 2001; 27:285.
  36. Tekola Ayele F, Adeyemo A, Finan C, et al. HLA class II locus and susceptibility to podoconiosis. N Engl J Med 2012; 366:1200.
  37. Franco-Paredes C, Hidron A, Steinberg J. A woman from British Guyana with recurrent back pain and fever. Chyluria associated with infection due to Wuchereria bancrofti. Clin Infect Dis 2006; 42:1297, 1340.
  38. Dreyer G, Ottesen EA, Galdino E, et al. Renal abnormalities in microfilaremic patients with Bancroftian filariasis. Am J Trop Med Hyg 1992; 46:745.